Moderna's RSV Vaccine for Seniors Gains FDA Approval
TL;DR
Moderna's stock fell after the FDA approved its second product, an RSV vaccine named mResvia, which targets respiratory syncytial virus in older adults. This approval further validates Moderna's mRNA technology, also used in its Covid vaccine. Despite the stock dip, analysts project significant future sales growth for the RSV vaccine, potentially giving Moderna an edge over competitors Pfizer and GSK. Moderna's pre-filled syringe for the vaccine could simplify administration in pharmacies, enhancing its market position.
Topics:businessbusinesshealthcare#businesshealthcare#fda-approval#moderna#mrna-technology#rsv-vaccine#stock-performance
- Moderna Stock: Biotech Wins Second Drug Approval. Why Its RSV Vaccine Could Dominate Investor's Business Daily
- FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product CNBC
- FDA approves Moderna’s mRNA RSV vaccine for older adults CNN
- Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R) Yahoo Finance
- US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label Reuters
Want the full story? Read the original reporting
Read on Investor's Business Daily